Please use this identifier to cite or link to this item:
http://10.1.7.192:80/jspui/handle/123456789/12196
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mahobiya, Reetisha | - |
dc.date.accessioned | 2024-07-06T06:34:19Z | - |
dc.date.available | 2024-07-06T06:34:19Z | - |
dc.date.issued | 2024-05 | - |
dc.identifier.uri | http://10.1.7.192:80/jspui/handle/123456789/12196 | - |
dc.description.abstract | INTRODUCTION – Schizophrenia is a complex disorder wherein a patient develops positive, negative and cognitive symptoms. These symptoms altogether influence brain development. Positive symptoms include hallucinations, recurrent psychosis and delusions, Negative symptoms include social withdrawal, anhedonia, reduced energy, and cognitive symptoms include impairment in attention, memory, speech and gradual loss of working memory. These symptoms disrupt a person’s thoughts and effects. In addition to it, relapses of schizophrenic episodes are frequent and these patients are generally not aware of their illness. These symptoms are linked to high rates of non-adherence, more frequent relapses and worse disease outcomes. Treatment includes oral therapy with first of second-generation antipsychotics but are generally said to give poor response due to frequent dosing and patient non-compliance. In situ forming implants offers extended release of drugs eliminating frequency of dosing thereby increasing patient compliance. These depots are formed by suspending drug and a biodegradable polymer like PLGA in any biocompatible solvent and are administered subcutaneously. These form implant at the site of injection and release drug slowly corresponding to the polymer degradation. | en_US |
dc.publisher | Institute of Pharmacy, Nirma University, A'bad | en_US |
dc.relation.ispartofseries | PDR00811; | - |
dc.subject | Dissertation Report | en_US |
dc.subject | Pharmaceutics | en_US |
dc.subject | 22MPH | en_US |
dc.subject | 22MPH111 | en_US |
dc.subject | PDR00811 | en_US |
dc.title | Preparation and Optimization of Long-Acting In-Situ Forming Implant Based Formulation of An Anti-Psychotic Drug | en_US |
dc.type | Dissertation | en_US |
Appears in Collections: | M.Pharm. Research Reports, Department of Pharmaceutical Technology and Biopharmaceutics |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PDR00811_22MPH111.pdf | PDR00811 | 3.56 MB | Adobe PDF | ![]() View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.